This $87B Healthcare Giant Is 61% Undervalued

Policy fears created a buying opportunity in this hospital leader ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

BROUGHT TO YOU BY MANWARD PRESS Dealmaker's Diary: Policy Panic Creates a 61% Value Play in This $87B Healthcare Giant SPONSORED Elon Musk’s Final Project REVEALED It's a secret project … bigger than Tesla … bigger than SpaceX … and bigger than Twitter. Inside this warehouse in Memphis Tennessee… Lies a new technology that is 100,000 times more powerful than Nvidia’s most advanced AI chip. Nvidia’s CEO is even considering investing in this project directly. Get the full details on Elon’s secret new AI project now.   Alpesh Patel Quantitative Investing Specialist The more Washington talks about healthcare reform, the cheaper this stock gets. Which is exactly what makes it interesting. While politicians debate policy, this $87 billion healthcare leader keeps doing what it does best - operating the largest network of hospitals in America and generating $65 billion in annual revenue. SPONSORED The Chance Meeting That Made Alex a Fortune Sometimes, the best investment advice comes from where you least expect it. For Alexander Green, it was from a casual chat during a basketball game 30 years ago. Uncover how this unexpected advice led to the biggest wins of Alex's career. Click here to learn this secret.   The market is pricing in catastrophe. The reality is much different: Healthcare demand is inelastic - people don't stop needing medical care. This company has survived every policy storm for decades. AI integration is driving operational efficiency to new levels. The stock trades at a 61% discount to fair value on discounted cash flow analysis. Smart money knows that the best opportunities come when fear overrides fundamentals. When a defensive giant with 11.8% CROCI trades at 14.2 forward P/E because of political noise, contrarian investors take notice. Click here or on the image below to see why Washington's healthcare fears could make you wealthy. Happy hunting, Alpesh WATCH THE VIDEO (WITH TRANSCRIPT) SPONSORED Alexander Green was ahead of the curve and added Palantir to his portfolio on September 19, and it's already proving to be one of his sharpest calls this year. Since adding it to the portfolio, the stock is up an astonishing 92% - with no signs of slowing down. Alex believes Palantir could be one of the "Next Magnificent Seven" Stocks. He's comparing it to Apple, Amazon, Nvidia , which he called years before its meteoric rise. If you missed the mag 7's early breakout, you don't want to make the same mistake here.   Want more content like this? YES NO

Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2025 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.